<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03374267</url>
  </required_header>
  <id_info>
    <org_study_id>iOM-110363</org_study_id>
    <nct_id>NCT03374267</nct_id>
  </id_info>
  <brief_title>Registry Platform Renal Cell Carcinoma</brief_title>
  <acronym>CARAT</acronym>
  <official_title>Clinical Research Platform On Renal Cell Carcinoma Treatment And Outcome (Registry Platform Renal Cell Carcinoma; CARAT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>iOMEDICO AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>iOMEDICO AG</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the project is to set up a national, prospective, longitudinal, multicenter
      cohort study with associated satellites, a tumor registry platform, to document uniform data
      on characteristics, molecular diagnostics, treatment and course of disease, to collect
      patient-reported outcomes and to establish a decentralized biobank for patients with advanced
      Renal Cell Carcinoma in Germany.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      CARAT is a national, observational, prospective, longitudinal, multicenter cohort study
      (tumor registry platform) with the purpose to record information on the antineoplastic
      treatment of renal cell carcinoma in Germany. The registry will follow patients for up to
      three years. It will identify common therapeutic sequences and changes in the treatment of
      the disease. At inclusion, data in patient characteristics, comorbidities, tumor
      characteristics and previous treatments are collected. During the course of observation data
      on all systemic treatments, radiotherapies, surgeries, and outcome are documented.

      Health-related quality of life (HRQoL) in patients with renal cell carcinoma will be
      evaluated for up to two years.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 7, 2017</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Anticipated">December 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Course of treatment (treatment reality)</measure>
    <time_frame>3 years per patient</time_frame>
    <description>Documentation of anamnestic data and therapy sequences</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Best Response</measure>
    <time_frame>3 years per patient</time_frame>
    <description>Documentation of response rates per line of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>3 years per patient</time_frame>
    <description>Documentation of progression-free survival per line of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>3 years per patient</time_frame>
    <description>Documentation of overall survival time.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-related quality of life (Patient-reported outcome)</measure>
    <time_frame>2 years per patient</time_frame>
    <description>National Comprehensive Cancer Network/ Functional Assessment of Cancer Therapy (FACT)-Kidney Symptom Index 19 (NCCN-FACT FKSI-19)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment symptom related quality of life</measure>
    <time_frame>2 years per patient</time_frame>
    <description>Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE™) - Items/Scores: 3/7/15/22/24/27/28/50/51</description>
  </secondary_outcome>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Renal Cell Carcinoma</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Routine care as per site standard.</intervention_name>
    <description>Physician's choice according to patient's needs.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adult patients with advanced renal cell carcionoma (aRCC) requiring systemic treatment
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female and male patients with aRCC (locally advanced, inoperable or metastatic)

          -  Patients at start of their first-line systemic treatment for aRCC

          -  Written informed consent

               -  Patients participating in the PRO module: signing of in-formed consent form and
                  completion of baseline questionnaire before start of initial systemic treatment

               -  Patients not participating in the PRO module: within twelve weeks after start of
                  systemic first-line for aRCC

          -  Age ≥ 18 years

          -  Patients participating in the PRO module: Sufficient knowledge of the German language
             to fill-in the questionnaires

        Exclusion Criteria:

          -  Patients with prior systemic therapy for aRCC

          -  No systemic treatment for aRCC
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Staehler, Prof. Dr.</last_name>
    <role>Study Chair</role>
    <affiliation>Urologische Klinik und Poliklinik, Klinikum der Universität München</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Peder Goebell, PD Dr.</last_name>
    <role>Study Chair</role>
    <affiliation>Urologische Universitätsklinik, Waldkrankenhaus St. Marien</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Norbert Marschner, Dr.</last_name>
    <role>Study Chair</role>
    <affiliation>Praxis für interdisziplinäre Onkologie &amp; Hämatologie</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lothar Müller, Dr.</last_name>
    <role>Study Chair</role>
    <affiliation>Onkologie Leer - Emden - Papenburg</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Adrian Binninger</last_name>
    <phone>+49 761 15242-0</phone>
    <email>info@iomedico.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Multiple sites, Germany</name>
      <address>
        <city>Multiple Locations</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>iOMEDICO AG</last_name>
      <phone>+49 761 152420</phone>
      <email>info@iomedico.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 12, 2017</study_first_submitted>
  <study_first_submitted_qc>December 12, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 15, 2017</study_first_posted>
  <last_update_submitted>January 4, 2018</last_update_submitted>
  <last_update_submitted_qc>January 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

